An Observational Study of Treatment, Outcomes, and Prognosis in Patients With Follicular Non-Hodgkin's Lymphoma

Sponsor
Genentech, Inc. (Industry)
Overall Status
Completed
CT.gov ID
NCT00097565
Collaborator
(none)
2,740
120

Study Details

Study Description

Brief Summary

This is a prospective, observational, longitudinal, multicenter study of patients with newly diagnosed follicular Non Hodgkin's Lymphoma (NHL) designed to delineate differences in clinical outcome by comparing the effectiveness and safety of common treatment regimens.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    2740 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    The National Lymphocare Study: An Observational Study of Treatment, Outcomes, and Prognosis in Patients With Follicular Non-Hodgkin's Lymphoma
    Actual Study Start Date :
    Mar 1, 2004
    Actual Primary Completion Date :
    Mar 1, 2014
    Actual Study Completion Date :
    Mar 1, 2014

    Outcome Measures

    Primary Outcome Measures

      Eligibility Criteria

      Criteria

      Ages Eligible for Study:
      18 Years and Older
      Sexes Eligible for Study:
      All
      Accepts Healthy Volunteers:
      No
      Inclusion Criteria:
      • Signed Informed Consent Form (unless the Institutional Review Board [IRB] has granted a waiver of consent)

      • Signed Authorization for the Use and Disclosure of Health Information document

      • Age ≥18 years

      • Histologic documentation of follicular NHL, according to Revised European-American Lymphoma (REAL) classification system, as assessed by the local pathologist and treating physician

      • Initial diagnosis of follicular B-cell NHL within 6 months prior to enrollment

      • Availability of cancer-specific historical data points in the patient's medical records

      Exclusion Criteria:
      • Other indolent or histologic NHL subtypes

      • Diagnosis of lymphoma > 6 months prior to enrollment

      Contacts and Locations

      Locations

      No locations specified.

      Sponsors and Collaborators

      • Genentech, Inc.

      Investigators

      • Study Director: Cinical Trials, Genentech, Inc.

      Study Documents (Full-Text)

      None provided.

      More Information

      Publications

      None provided.
      Responsible Party:
      Genentech, Inc.
      ClinicalTrials.gov Identifier:
      NCT00097565
      Other Study ID Numbers:
      • U2963n
      First Posted:
      Nov 25, 2004
      Last Update Posted:
      Mar 23, 2017
      Last Verified:
      Mar 1, 2017
      Keywords provided by Genentech, Inc.
      Additional relevant MeSH terms:

      Study Results

      No Results Posted as of Mar 23, 2017